Bedrock Therapeutics, Inc.
Chapel Hill, NC · Biotech · Private
Gene therapy using HLA-G to modulate immune response and prevent ocular graft-versus-host disease
- Grants
- $3.6M
- 9 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Develop humanized AAV vectors for liver targeting and neutralizing antibody evasion | $249,310 | |
| Federal grant | Department of Health and Human Services · Phase I · Prevention of corneal transplant rejection using AAV-HLA-G combination therapy | $250,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Prevention of corneal transplant rejection using AAV-HLA-G combination therapy | $171,923 | |
| Federal grant | Department of Health and Human Services · Phase I · Immunosuppressive Gene Therapy for Ocular Graft vs Host Disease | $328,150 | |
| Federal grant | Department of Health and Human Services · Phase I · Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasion | $261,080 | |
| Federal grant | Department of Health and Human Services · Phase II · Prevention of corneal transplant rejection using AAV-BDRK-401 therapy | $975,387 | |
| Federal grant | Department of Health and Human Services · Phase I · Vector mediated anti-vascular and anti-inflammatory therapy for AMD | $310,952 | |
| Federal grant | Department of Health and Human Services · Phase II · Prevention of corneal transplant rejection using AAV-BDRK-401 therapy | $793,930 | |
| Federal grant | Department of Health and Human Services · Phase I · Intramuscular Administration of AAV Vectors Encoding soluble PD-L1 for Rheumatoid Arthritis Treatment | $304,502 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1404 | On Target Therapeutics, LLC | — | — |
| 1405 | CRYOCRATE LLC | — | — |
| 1406 | DD Therapeutics, LLC | — | — |
| 1407 | Bedrock Therapeutics, Inc. | — | — |
| 1408 | Integrated Protein Technologies, Inc. | — | — |
| 1409 | PHOTONIC PHARMA, LLC | — | — |
| 1410 | GIGAMUNE, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.